Lexicon Pharmaceuticals

Yahoo Finance • yesterday

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to enhance current and future legislative and... Full story

Yahoo Finance • 17 days ago

Lexicon reports FDA's decision to extend review period for Zynquista

[Heart Health Concept] Eoneren/E+ via Getty Images Lexicon Pharmaceuticals (NASDAQ:LXRX [https://seekingalpha.com/symbol/LXRX]) said that the FDA has asked for additional time to review additional data for the potential resubmission of th... Full story

Yahoo Finance • 17 days ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmis... Full story

Yahoo Finance • 22 days ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for its investigational, AAK1-inhibitor, p... Full story

Yahoo Finance • 28 days ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of the data across Phase 2 program to be discussed at Arrowhead’s 19th Annu... Full story

Yahoo Finance • last month

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on reasonable path forward for Zynquista NDA resubmis... Full story

Yahoo Finance • last month

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain... Full story

Yahoo Finance • 2 months ago

Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) Q2 2025 Earnings: Revenue Soars 482% Above Estimates, Stock Gains 9.5%

LEXICON PHARMACEUTICALS (NASDAQ:LXRX) REPORTS Q2 2025 EARNINGS: REVENUE SURPASSES ESTIMATES, MARKET REACTS POSITIVELY Lexicon Pharmaceuticals Inc (NASDAQ:LXRX [https://www.chartmill.com/stock/quote/LXRX]) reported its second-quarter 2025... Full story

Yahoo Finance • 2 months ago

Lexicon Pharmaceuticals GAAP EPS of $0.01 beats by $0.09, revenue of $28.87M

* Lexicon Pharmaceuticals press release [https://seekingalpha.com/pr/20190800-lexicon-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:LXRX [https://seekingalpha.com/symbol/LXRX]): Q2 GAAP EPS... Full story

Yahoo Finance • 2 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Partnership discussions for pilavapadin remain underway following Phase 2b PROGRESS study results IND-enabling studies of LX9851 for obesity and related disorders on track for completion in 2025 with licensee Novo Nordisk expected to subm... Full story

Yahoo Finance • 3 months ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

THE WOODLANDS, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2025 financial results on Wednesday, August 6, 2025, prior to market open. M... Full story

Yahoo Finance • 3 months ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral neuropathic pain (DPNP) despite treatmen... Full story

Yahoo Finance • 3 months ago

Lexicon Q1 2025 slides: EPS beat, revenue miss, strategic partnerships advance

Introduction & Market Context Lexicon Pharmaceuticals (NASDAQ:LXRX) presented its first quarter 2025 earnings on May 13, highlighting financial restructuring efforts and strategic partnerships amid ongoing revenue challenges. The company... Full story

Yahoo Finance • 4 months ago

H.C. Wainwright reiterates buy rating on Lexicon Pharmaceuticals stock

Investing.com - H.C. Wainwright maintained its buy rating and $4.00 price target on Lexicon Pharmaceuticals (NASDAQ:LXRX) stock following new data presented at the American Diabetes Association conference. With the stock currently tradin... Full story

Yahoo Finance • 5 months ago

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was one of the stocks that was covered in that article. Wall Street analysts believe LXRX has a 285% upside po... Full story

Yahoo Finance • 5 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Release Date: May 13, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) announced an exclusive license agreement with Novo... Full story

Yahoo Finance • 5 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Confere... Full story

Yahoo Finance • 6 months ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S for LX9851, a first-in-class, oral non-in... Full story

Yahoo Finance • 7 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

THE WOODLANDS, Texas, March 07, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference 2025 i... Full story

Yahoo Finance • 7 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on Advancing Strong Pipeline Conference Call a... Full story